紫杉醇联合5-氟尿嘧啶、奈达铂治疗晚期食管癌的临床观察  

Clinical Study of Paclitaxel Combined with Nedaplatin and 5-Fu in the Treatment of Advanced Esophageal Cancer

作　　者：陈英[1] 

机构地区：[1]江苏省启东市第三人民医院内科,226200

出　　处：《医学理论与实践》2008年第11期1259-1260,共2页The Journal of Medical Theory and Practice

摘　　要：目的：观察紫杉醇（PTX）联合5-氟尿嘧啶（5-Fu）、奈达铂（NDP）治疗晚期食管癌的近期疗效和不良反应。方法：晚期食管癌患者35例，紫杉醇135-175mg／m^2，静脉滴注，第1天；奈达铂80-100mg／m^2，加入生理盐水500ml中静滴2h，第2天；5-Fu500mg/m^2，静脉滴注，第1天-第5天；21d为1周期，连用2个周期后评价疗效。结果：全组35例可评价疗效，总有效率60.0％（21／35），完全缓解2例，部分缓解19例，中位生存期为9.7个月（3.5-22个月），中位缓解时间为4.6个月（3-7个月），主要不良反应为骨髓抑制所致的血小板及白细胞减少，消化道反应轻，未发现肝肾功能损害。结论：紫杉醇联合5-氟尿嘧啶、奈达铂治疗晚期食管癌近期疗效高，耐受性好，值得进一步观察应用。Objective：To evaluate the efficiency and toxicity of combination chemotherapy with paclitaxel, nedaplatin and 5-Fu in the treatment of advanced esophageal cancer. Methods： 35 cases were treated with TPF regimen, PTX 135-175mg/m^2 ,iv, dl;NDP 80-100mg/m^2 ,iv,d2;5-Fu 500mg/m^2, iv, d1-d5. The cycle was repeated every 21 days. After two consecutive treatment course, the evaluation of the short term efficacy and adverse effects was carried out. Results：The overall response rate was 60.0%（21/35）, with CR 5.7%（2/35）, PR 54.3%（19/35）. The median overall survival of the whole group was 9.7 months（3.5-22months）,the median time to progress was 4. 6months（3-7months）. The major toxicity and side effects were myelosuppression and thrombocytopenia, nausea and vomiting, which were mild to moderate. Conclusion. TPF is effective for the advanced esophageal cancer and the toxicity and side effects are tolerable.

关 键 词：紫杉醇 奈达铂 食管癌 联合化疗 

分 类 号：R735.1[医药卫生—肿瘤] R453.9[医药卫生—临床医学]